XML 29 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended 129 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Cash flows used in operating activities:      
Net loss $ (3,480) $ (3,734) $ (67,154)
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain on bargain purchase       (25,282)
Gain on patent rights assignment    (2,000) (2,000)
Depreciation and amortization 34 518 1,771
Non-cash interest expense       211
Share-based compensation 243 232 2,525
Issuance of warrants for lease termination       377
Accretion of liabilities       152
Impairment of property and equipment       125
Impairment of in-process research and development       6,000
Write-off of deferred tax liability       (2,281)
Gain on marketable securities available for sale       (263)
(Gain) loss from disposal of property and equipment    4 83
Other, net       267
Change in operating assets and liabilities (net of amounts acquired):      
Other current assets 219 (56) 2,761
Other assets 60 60 7,306
Accounts payable (141) (104) (2,071)
Accrued expenses and other liabilities (318) (384) (19,302)
Deferred rent (25) (259) 24
Net cash used in operating activities (3,408) (5,723) (96,751)
Cash flows (used in) provided by investing activities:      
Cash received from Merger       30,392
Payment of deferred transaction costs       (1,186)
Purchase of property and equipment (1) (1) (1,880)
Proceeds from sale of marketable securities       15,369
Proceeds from sale of property and equipment    2 358
Proceeds from assignment of patent rights    2,000 2,000
Net cash (used in) provided by investing activities (1) 2,001 45,053
Cash flows (used in) provided by financing activities:      
Proceeds from issuance of convertible notes payable and related warrants for common stock       10,841
Proceeds from issuance of bank note payable       4,000
Proceeds from stock subject to repurchase       38
Proceeds from the issuance of preferred stock       32,316
Proceeds from the issuance of common stock 953 3,001 13,534
Repayment of principal on bank note payable       (4,000)
Repayment of principal on convertible notes payables       (105)
Repayment of principal on vendor finance agreement (134) (97) (280)
Net cash (used in) provided by financing activities 547 2,445 54,779
Net (decrease) increase in cash and cash equivalents (2,862) (1,277) 3,081
Cash and cash equivalents, beginning of period 5,943 7,025  
Cash and cash equivalents, end of period 3,081 5,748 3,081
Supplemental cash flow information:      
Interest paid 3 4 115
Supplemental disclosure of noncash investing and financing transactions:      
Accrued interest on notes payable converted to equity       163
Warrant issued in connection with credit facility       111
Accrued deferred transaction costs       482
Vendor finance agreement    50   
Common Stock
      
Cash flows (used in) provided by financing activities:      
Payment of offering costs (272) (459) (1,319)
Preferred Stock
      
Cash flows (used in) provided by financing activities:      
Payment of offering costs       $ (246)